-
EP3897640
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3897640
| EP3897640 - QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 11.10.2024 Database last updated on 07.04.2026 | |
| Former | Request for examination was made Status updated on 24.09.2021 | ||
| Former | The international publication has been made Status updated on 02.07.2020 | ||
| Former | unknown Status updated on 11.01.2020 | Most recent event Tooltip | 30.12.2025 | New entry: Renewal fee paid | Applicant(s) | For all designated states ABIVAX 7-11 Boulevard Haussmann 75009 Paris / FR | For all designated states Institut Curie 26, rue d'Ulm 75248 Paris Cedex 05 / FR | For all designated states UNIVERSITE DE MONTPELLIER 163, rue Auguste Broussonnet 34090 Montpellier / FR | For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75794 Paris Cedex 16 / FR | [2023/09] |
| Former [2021/43] | For all designated states ABIVAX 5 rue de la Baume 75008 Paris / FR | ||
| For all designated states Institut Curie 26, rue d'Ulm 75248 Paris Cedex 05 / FR | |||
| For all designated states UNIVERSITE DE MONTPELLIER 163, rue Auguste Broussonnet 34090 Montpellier / FR | |||
| For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75794 Paris Cedex 16 / FR | Inventor(s) | 01 /
POULETTY, Philippe 3 rue Maître Albert 75005 PARIS / FR | 02 /
EHRLICH, Hartmut 15 rue Raynouard 75016 PARIS / FR | 03 /
SCHERRER, Didier 18 avenue de la Fée Mélusine 34170 CASTELNAU LE LEZ / FR | 04 /
TAZI, Jamal 4 rue Condorcet 34380 CLAPIERS / FR | [2021/43] | Representative(s) | Ipsilon 12 Avenue d'Italie 75013 Paris / FR | [N/P] |
| Former [2021/43] | Nony 11 rue Saint-Georges 75009 Paris / FR | Application number, filing date | 19829571.9 | 19.12.2019 | [2021/43] | WO2019EP86477 | Priority number, date | EP20180306782 | 20.12.2018 Original published format: EP 18306782 | [2021/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020127843 | Date: | 25.06.2020 | Language: | EN | [2020/26] | Type: | A1 Application with search report | No.: | EP3897640 | Date: | 27.10.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.06.2020 takes the place of the publication of the European patent application. | [2021/43] | Search report(s) | International search report - published on: | EP | 25.06.2020 | Classification | IPC: | A61K31/47, A61K31/4709, A61K31/497, A61K31/5377, C07H17/02, A61P29/00 | [2021/43] | CPC: |
A61K31/47 (EP,IL,KR);
C07D215/38 (KR);
A61K31/706 (KR,US);
A61K31/4709 (EP,IL,KR);
A61K31/497 (EP,IL);
A61K31/5377 (EP,IL,KR);
A61K31/661 (KR);
A61P1/16 (US);
A61P29/00 (EP,IL,KR);
A61P9/12 (US);
C07D401/12 (KR);
C07F9/062 (KR);
C07H17/02 (EP,IL,KR)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/43] | Extension states | BA | 20.07.2021 | ME | 20.07.2021 | Validation states | KH | 20.07.2021 | MA | 20.07.2021 | MD | 20.07.2021 | TN | 20.07.2021 | Title | German: | CHINOLINDERIVATE ZUR VERWENDUNG IN DER BEHANDLUNG VON ENTZÜNDUNGSKRANKHEITEN | [2021/43] | English: | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | [2021/43] | French: | DÉRIVÉS DE QUINOLÉINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES | [2021/43] | Entry into regional phase | 20.07.2021 | National basic fee paid | 20.07.2021 | Designation fee(s) paid | 20.07.2021 | Examination fee paid | Examination procedure | 28.06.2021 | Amendment by applicant (claims and/or description) | 20.07.2021 | Examination requested [2021/43] | 20.07.2021 | Date on which the examining division has become responsible | 15.10.2024 | Despatch of a communication from the examining division (Time limit: M04) | 10.02.2025 | Reply to a communication from the examining division | Fees paid | Renewal fee | 03.01.2022 | Renewal fee patent year 03 | 02.01.2023 | Renewal fee patent year 04 | 02.01.2024 | Renewal fee patent year 05 | 27.12.2024 | Renewal fee patent year 06 | 29.12.2025 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY] WO2016009065 (ABIVAX et al.) | [Y] WO2016009066 (ABIVAX et al.) | [Y] WO2016135055 (ABIVAX et al.) | [Y] KARIM CHEBLI ET AL: "The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages", SCIENTIFIC REPORTS, vol. 7, no. 1, 7 July 2017 (2017-07-07), XP055588680, DOI: 10.1038/s41598-017-04071-3 DOI: http://dx.doi.org/10.1038/s41598-017-04071-3 | [Y] ANONYMOUS: "Abivax sets its course on colitis and Crohn's - Pharmaphorum", 4 September 2018 (2018-09-04), XP055588690, Retrieved from the Internet | [YP] AUDREY VAUTRIN ET AL: "Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing", SCIENTIFIC REPORTS, 12 January 2019 (2019-01-12), London, pages 1 - 15, XP055565970, Retrieved from the Internet DOI: http://dx.doi.org/10.1038/s41598-018-37813-y | by applicant | WO2010143169 | WO2012080953 | WO2016009065 | WO2016009066 | WO2014111892 | S. M. BERGE ET AL.: "pharmaceutically acceptable salts", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 | SANYAL AJ. ET AL., HEPATOLOGY, vol. 54, 2011, pages 344 | KLEINER DE ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313 |